Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target Raised to $137.00 at Royal Bank Of Canada

Rhythm Pharmaceuticals (NASDAQ:RYTM) had its price objective boosted by equities researchers at Royal Bank Of Canada from $136.00 to $137.00 in a research note issued on Wednesday,Benzinga reports. The firm currently has an “outperform” rating on the stock. Royal Bank Of Canada’s target price would suggest a potential upside of 45.26% from the stock’s previous close.

A number of other equities research analysts have also commented on RYTM. Needham & Company LLC lowered their price target on shares of Rhythm Pharmaceuticals from $139.00 to $130.00 and set a “buy” rating for the company in a report on Tuesday, March 17th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Rhythm Pharmaceuticals in a report on Tuesday, April 21st. Zacks Research upgraded shares of Rhythm Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 17th. Morgan Stanley decreased their price objective on shares of Rhythm Pharmaceuticals from $150.00 to $136.00 and set an “overweight” rating for the company in a report on Tuesday, March 17th. Finally, Bank of America decreased their price objective on shares of Rhythm Pharmaceuticals from $145.00 to $139.00 and set a “buy” rating for the company in a report on Tuesday, March 17th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Rhythm Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $131.63.

Rhythm Pharmaceuticals Stock Performance

NASDAQ:RYTM traded up $2.01 during midday trading on Wednesday, reaching $94.32. 425,515 shares of the stock traded hands, compared to its average volume of 783,245. The company has a fifty day moving average of $87.97 and a 200 day moving average of $99.44. Rhythm Pharmaceuticals has a 12 month low of $55.31 and a 12 month high of $122.20. The stock has a market capitalization of $6.46 billion, a P/E ratio of -30.33 and a beta of 1.94.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($0.83) EPS for the quarter, beating analysts’ consensus estimates of ($0.86) by $0.03. Rhythm Pharmaceuticals had a negative net margin of 103.57% and a negative return on equity of 266.56%. The company had revenue of $60.11 million during the quarter, compared to analyst estimates of $55.78 million. During the same period in the prior year, the business posted ($0.81) EPS. The firm’s revenue was up 83.8% compared to the same quarter last year. On average, analysts predict that Rhythm Pharmaceuticals will post -3.08 EPS for the current fiscal year.

Insider Buying and Selling at Rhythm Pharmaceuticals

In other Rhythm Pharmaceuticals news, CFO Hunter C. Smith sold 4,385 shares of the company’s stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $101.26, for a total value of $444,025.10. Following the completion of the transaction, the chief financial officer directly owned 110,512 shares in the company, valued at approximately $11,190,445.12. This represents a 3.82% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Christopher Paul German sold 5,614 shares of the company’s stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $89.56, for a total transaction of $502,789.84. Following the completion of the sale, the chief accounting officer directly owned 160 shares in the company, valued at $14,329.60. This represents a 97.23% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 24,020 shares of company stock valued at $2,375,805 over the last 90 days. Company insiders own 6.10% of the company’s stock.

Institutional Trading of Rhythm Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of RYTM. AQR Capital Management LLC grew its position in shares of Rhythm Pharmaceuticals by 148.2% in the 1st quarter. AQR Capital Management LLC now owns 39,363 shares of the company’s stock worth $2,085,000 after buying an additional 23,506 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Rhythm Pharmaceuticals by 6.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 35,282 shares of the company’s stock worth $1,874,000 after buying an additional 2,126 shares during the period. Prudential Financial Inc. grew its position in shares of Rhythm Pharmaceuticals by 62.9% in the 2nd quarter. Prudential Financial Inc. now owns 7,095 shares of the company’s stock worth $423,000 after buying an additional 2,740 shares during the period. Qube Research & Technologies Ltd grew its position in shares of Rhythm Pharmaceuticals by 11.2% in the 2nd quarter. Qube Research & Technologies Ltd now owns 240,345 shares of the company’s stock worth $15,187,000 after buying an additional 24,152 shares during the period. Finally, Sei Investments Co. grew its position in shares of Rhythm Pharmaceuticals by 10.0% in the 2nd quarter. Sei Investments Co. now owns 33,145 shares of the company’s stock worth $2,095,000 after buying an additional 3,004 shares during the period.

More Rhythm Pharmaceuticals News

Here are the key news stories impacting Rhythm Pharmaceuticals this week:

• Positive Sentiment: Wells Fargo raised its price target slightly to $144 and kept an “overweight” rating, signaling continued analyst confidence and implying material upside from current levels. Benzinga
• Positive Sentiment: Company reported Q1 results that topped revenue and EPS consensus: $60.1M in net product revenue (IMCIVREE) and a small EPS beat (loss of $0.83 vs. est. -$0.86), showing early commercial traction and higher-than-expected sales growth. Press Release
• Positive Sentiment: Commercial and regulatory milestones: U.S. launch into acquired hypothalamic obesity with >150 patient start forms in six weeks, European Commission marketing authorization for acquired hypothalamic obesity, and an ongoing Japanese review — all support multi-region growth potential for IMCIVREE. Press Release
• Positive Sentiment: New clinical data presentations at the Pediatric Endocrine Society increase scientific visibility for IMCIVREE in acquired hypothalamic obesity, which can support uptake and payer discussions. Business Insider
• Neutral Sentiment: CEO David Meeker will appear at the Bank of America Global Healthcare Conference (May 13), offering investors a forum for updated commercial guidance and Q&A that could move sentiment depending on commentary. GlobeNewswire
• Neutral Sentiment: Market and analyst coverage pieces are highlighting IMCIVREE’s long-term potential and shifting narrative as early commercial data arrive; these stories can amplify investor interest but are commentary rather than new fundamentals. Yahoo
• Negative Sentiment: Profitability remains negative: Rhythm still reports negative net margin (~103.6%) and very negative ROE, reflecting early commercial-stage economics and R&D spend — a reminder that cash burn and margin improvement are watch items. MarketBeat

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.

The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.